The University of Southampton
University of Southampton Institutional Repository

Ultramolecular homeopathy has no observable clinical effects. A randomized, double-blind, placebo-controlled proving trial of Belladonna 30C

Ultramolecular homeopathy has no observable clinical effects. A randomized, double-blind, placebo-controlled proving trial of Belladonna 30C
Ultramolecular homeopathy has no observable clinical effects. A randomized, double-blind, placebo-controlled proving trial of Belladonna 30C
AIMS: To investigate if ultramolecular homeopathy has any clinical effects. This was assessed using the proving of the homeopathic remedy Belladonna given at an ultramolecular dose (30C), as a model. A proving states that when a homeopathic remedy is given to a healthy person, they will experience symptomatic effects specific to that remedy. If ultramolecular doses are clinically active, the Belladonna 30C group should experience more true Belladonna proving symptoms than the placebo group. METHODS: Healthy subjects (n = 253), aged 18-30 years, took part in this double-blind, randomized placebo-controlled study. Total study duration was 4 weeks. Subjects were randomized before 1 week placebo run-in. They received 2 weeks of treatment intervention (Belladonna 30C or placebo) and were followed up for 1 week. Subjects recorded any symptoms experienced during the total study period on a daily basis using a structured questionnaire. Symptom diaries were analysed blind to determine if each subject had proved or not (based on predefined criteria). The main outcome was the proportion of subjects who had proved in each treatment group. RESULTS: No significant group differences in proving rates were observed [Belladonna provers N = 14 (13.9%); placebo provers N = 15 (14.3%); mean difference -0.4%, 95% confidence interval -9.3, 10.1] based on intention to treat analysis. Primary outcome was not affected by seasonality or the individual's attitude to complementary medicine. CONCLUSION: Ultramolecular homeopathy had no observable clinical effects
female, adolescent, non-u.s.gov't, therapeutic use, research support, male, atropa belladonna, hay fever, aged, homeopathy, clinical-trial, adult, pilot projects, double-blind method, analysis, attitude, humans, research, treatment, methods, double-blind, therapy, materia medica
0007-1188
562-568
Brien, S.
4e8e97cd-7bc3-4efd-857e-20790040b80f
Lewith, G.
0fc483fa-f17b-47c5-94d9-5c15e65a7625
Bryant, T.
6cc3c2b2-6dd5-46fc-bbf7-496f4e3483d8
Brien, S., Lewith, G. and Bryant, T. (2003) Ultramolecular homeopathy has no observable clinical effects. A randomized, double-blind, placebo-controlled proving trial of Belladonna 30C British Journal of Pharmacology, 56, (5), pp. 562-568. (doi:10.1046/j.1365-2125.2003.01900.x).

Brien, S., Lewith, G. and Bryant, T. (2003) Ultramolecular homeopathy has no observable clinical effects. A randomized, double-blind, placebo-controlled proving trial of Belladonna 30C British Journal of Pharmacology, 56, (5), pp. 562-568. (doi:10.1046/j.1365-2125.2003.01900.x).

Record type: Article

Abstract

AIMS: To investigate if ultramolecular homeopathy has any clinical effects. This was assessed using the proving of the homeopathic remedy Belladonna given at an ultramolecular dose (30C), as a model. A proving states that when a homeopathic remedy is given to a healthy person, they will experience symptomatic effects specific to that remedy. If ultramolecular doses are clinically active, the Belladonna 30C group should experience more true Belladonna proving symptoms than the placebo group. METHODS: Healthy subjects (n = 253), aged 18-30 years, took part in this double-blind, randomized placebo-controlled study. Total study duration was 4 weeks. Subjects were randomized before 1 week placebo run-in. They received 2 weeks of treatment intervention (Belladonna 30C or placebo) and were followed up for 1 week. Subjects recorded any symptoms experienced during the total study period on a daily basis using a structured questionnaire. Symptom diaries were analysed blind to determine if each subject had proved or not (based on predefined criteria). The main outcome was the proportion of subjects who had proved in each treatment group. RESULTS: No significant group differences in proving rates were observed [Belladonna provers N = 14 (13.9%); placebo provers N = 15 (14.3%); mean difference -0.4%, 95% confidence interval -9.3, 10.1] based on intention to treat analysis. Primary outcome was not affected by seasonality or the individual's attitude to complementary medicine. CONCLUSION: Ultramolecular homeopathy had no observable clinical effects

Full text not available from this repository.

More information

Published date: 2003
Keywords: female, adolescent, non-u.s.gov't, therapeutic use, research support, male, atropa belladonna, hay fever, aged, homeopathy, clinical-trial, adult, pilot projects, double-blind method, analysis, attitude, humans, research, treatment, methods, double-blind, therapy, materia medica

Identifiers

Local EPrints ID: 61677
URI: http://eprints.soton.ac.uk/id/eprint/61677
ISSN: 0007-1188
PURE UUID: b208b16b-afff-4615-a0b1-ff2e4167971c

Catalogue record

Date deposited: 08 Sep 2008
Last modified: 17 Jul 2017 14:21

Export record

Altmetrics

Contributors

Author: S. Brien
Author: G. Lewith
Author: T. Bryant

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×